Bioasis Technologies’ (BTI.V) xB3 platform is designed to deliver therapeutics across the blood brain barrier. BTI’s proprietary tech is relevant to the treatment of brain cancers and neurodegenerative diseases….
BTI.V
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according…
The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If…